This inventor holds 2 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignees: Bayer Intellectual Property Gmbh, Bayer Pharma Aktiengesellschaft. Active years: 2013-2017.
Company Filing History:
1 out of 721 
1 out of 386 
Years Active: 2013-2017
Title: Kornelia Kirchner: Pioneering Innovator in Antibody Development
Introduction
Kornelia Kirchner, an accomplished inventor based in Frechen, Germany, has made significant contributions to the field of biotechnology, particularly in the development of antibodies. With two patents to her name, she demonstrates a strong commitment to advancing scientific research and innovation.
Latest Patents
Kornelia Kirchner's latest patents focus on antibodies targeting tumor necrosis factor alpha (TNFα). These patents include not only the antibodies themselves but also their antigen-binding portions and derivatives capable of binding to TNFα. Additionally, she has developed nucleic acids encoding these antibodies and their complementary counterparts, vectors, and host cells containing these nucleic acids.
Career Highlights
Her professional journey includes notable experience at Bayer Pharma Aktiengesellschaft and Bayer Intellectual Property GmbH. During her time at these companies, Kornelia has been at the forefront of research and development in therapeutic innovations, particularly relating to immune response modulation.
Collaborations
Throughout her career, Kornelia Kirchner has collaborated with esteemed colleagues, including Christian Votsmeier and Uwe Gritzan. These partnerships have allowed for a dynamic exchange of ideas and fostered advancements in biomedicine.
Conclusion
Kornelia Kirchner stands out as a remarkable inventor whose work is paving the way for future advancements in the treatment of diseases influenced by TNFα. Her dedication to research and her collaborative spirit have undoubtedly left a mark on the industry, inspiring future innovators in biotechnology.